BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood 2015;125:3223-9. [DOI: 10.1182/blood-2015-01-588392] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review: Rituximab in Myasthenia Gravis. Muscle Nerve 2017;56:185-96. [DOI: 10.1002/mus.25597] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 22.8] [Reference Citation Analysis]
2 Raso S, Napolitano M, Arrigo G, Reale F, Lucchesi A, Silimbani P, Maggio A, Calvaruso G, Consoli U, Mannina D, Giordano G, Santoro M, Accurso V, Siragusa S. Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis. Ann Hematol 2021;100:653-9. [PMID: 33495923 DOI: 10.1007/s00277-021-04438-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kasinathan G, Sathar J. Mixed-type autoimmune hemolytic anaemia presenting as multiple thromboses: A case report. Ann Med Surg (Lond) 2020;60:323-6. [PMID: 33204423 DOI: 10.1016/j.amsu.2020.11.009] [Reference Citation Analysis]
4 Fang LW, Pan H, Shi J. [Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study]. Zhonghua Xue Ye Xue Za Zhi 2020;41:412-6. [PMID: 32536139 DOI: 10.3760/cma.j.issn.0253-2727.2020.05.009] [Reference Citation Analysis]
5 Szpakowski J, Tucker L, Baer DM, Pauly MP. Hepatotoxicity during legacy cancer chemotherapy in patients infected with hepatitis C virus: A retrospective cohort study. CanLivJ 2022;5:43-60. [DOI: 10.3138/canlivj-2021-0018] [Reference Citation Analysis]
6 Chen M, Zhuang J, Yang C, Zhang L, Wang W, Cai H, Yu Y, Li J, Zhou D, Han B. Rapid response to a single-dose rituximab combined with bortezomib in refractory and relapsed warm autoimmune hemolytic anemia. Ann Hematol 2020;99:1141-3. [DOI: 10.1007/s00277-020-03976-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Herishanu Y, Levi S, Kamdjou T, Bornstein Y, Ram R, Benyamini N, Varon D, Avivi I, Perry C. Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2021;192:e1-4. [PMID: 33095444 DOI: 10.1111/bjh.17105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Knops N, Emonds MP, Herman J, Levtchenko E, Mekahli D, Pirenne J, Van Geet C, Dierickx D. Bortezomib for autoimmune hemolytic anemia after intestinal transplantation. Pediatr Transplant 2020;24:e13700. [PMID: 32166874 DOI: 10.1111/petr.13700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Piatek CI, Bocian H, Algaze S, Weitz IC, O'Connell C, Liebman HA. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia. Acta Haematol 2020;143:244-9. [PMID: 31665725 DOI: 10.1159/000501538] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu AP, Cheuk DK. Disease-modifying treatments for primary autoimmune haemolytic anaemia. Cochrane Database Syst Rev 2021;3:CD012493. [PMID: 33786812 DOI: 10.1002/14651858.CD012493.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood 2017;129:2971-9. [PMID: 28360039 DOI: 10.1182/blood-2016-11-693689] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 14.0] [Reference Citation Analysis]
12 Santacruz JC, Mantilla MJ, Rueda I, Pulido S, Rodriguez-salas G, Londono J. A Practical Perspective of the Hematologic Manifestations of Systemic Lupus Erythematosus. Cureus. [DOI: 10.7759/cureus.22938] [Reference Citation Analysis]
13 Calhoun B, Moore A, Dickey A, Shoemaker DM. Systemic loxoscelism induced warm autoimmune hemolytic anemia: clinical series and review. Hematology 2022;27:543-54. [PMID: 35544675 DOI: 10.1080/16078454.2022.2065086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Yui JC, Brodsky RA. Updates in the Management of Warm Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.11.005] [Reference Citation Analysis]
15 Li X, Cai S, Zhong Z, Wang H, Wang L, You Y, Zhang M. Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report. Medicine (Baltimore) 2020;99:e19256. [PMID: 32118733 DOI: 10.1097/MD.0000000000019256] [Reference Citation Analysis]
16 Schultz LM, Majzner R, Davis KL, Mackall C. New developments in immunotherapy for pediatric solid tumors: . Current Opinion in Pediatrics 2018;30:30-9. [DOI: 10.1097/mop.0000000000000564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
17 Evangelatos G, Vlachadami I, Kechagia M, Iliopoulos A. Rituximab and lenalidomide combination treatment for rheumatoid arthritis complicated with myelodysplastic syndrome: A case report. Mediterr J Rheumatol 2017;28:217-20. [PMID: 32185287 DOI: 10.31138/mjr.28.4.217] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Li Y, Li JP, Li Y, Wang JY, Zhou XL, Mi YC, Zhou K, Peng GX, Ye L, Fan HH, Song L, Li P, Li Q, Zhao X, Yang Y, Gao QY, Yang WR, Jing LP, Zhang FK, Zhang L. [Low-dose rituximab in IgA-mediated autoimmune hemolytic anemia: a case report and literatures review]. Zhonghua Xue Ye Xue Za Zhi 2018;39:63-5. [PMID: 29551038 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.015] [Reference Citation Analysis]
19 Tsang M, Dahlin JL, Sundsted KK. 79-Year-Old Woman With Jaundice and Anemia. Mayo Clin Proc 2018;93:381-5. [PMID: 29258683 DOI: 10.1016/j.mayocp.2017.03.025] [Reference Citation Analysis]
20 Kuter DJ, Rogers KA, Boxer MA, Choi M, Agajanian R, Arnold DM, Broome CM, Field JJ, Murakhovskaya I, Numerof R, Tong S. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. Am J Hematol 2022;97:691-9. [PMID: 35179251 DOI: 10.1002/ajh.26508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Michel M, Jäger U. Autoimmune Hemolytic Anemia. Hematology. Elsevier; 2018. pp. 648-662.e1. [DOI: 10.1016/b978-0-323-35762-3.00046-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Xibillé-friedmann D, Pérez-rodríguez M, Carrillo-vázquez S, Álvarez-hernández E, Aceves FJ, Ocampo-torres MC, García-garcía C, García-figueroa JL, Merayo-chalico J, Barrera-vargas A, Portela-hernández M, Sicsik S, Andrade-ortega L, Rosales-don Pablo VM, Martínez A, Prieto-seyffert P, Pérez-cristóbal M, Saavedra MÁ, Castro-colín Z, Ramos A, Huerta-sil G, Hernández-cabrera MF, Jara LJ, Limón-camacho L, Tinajero-nieto L, Barile-fabris LA. Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología. Reumatología Clínica 2019;15:3-20. [DOI: 10.1016/j.reuma.2018.03.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
23 Murakhovskaya I. Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia. J Clin Med 2020;9:E4034. [PMID: 33322221 DOI: 10.3390/jcm9124034] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Liebman HA. Immune modulation for autoimmune disorders: evolution of therapeutics. Seminars in Hematology 2016;53:S23-6. [DOI: 10.1053/j.seminhematol.2016.04.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Barcellini W. Current treatment strategies in autoimmune hemolytic disorders. Expert Review of Hematology 2015;8:681-91. [DOI: 10.1586/17474086.2015.1073105] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
26 Elias S, Kahlon S, Kotzur R, Kaynan N, Mandelboim O. Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL). Oncoimmunology 2018;7:e1428158. [PMID: 29872553 DOI: 10.1080/2162402X.2018.1428158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hwang SR, Saliba AN, Wolanskyj-Spinner AP. Immunotherapy-associated Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am 2022;36:365-80. [PMID: 35339260 DOI: 10.1016/j.hoc.2021.11.002] [Reference Citation Analysis]
28 Gao QY, Liu CX, Li Y, Peng GX, Li JP, Li Y, Ye L, Fan HH, Song L, Zhang L, Jing LP, Zhou K, Zhao X, Yang WR, Wu ZJ, Yang Y, Xiong YZ, Zhang FK. [A monocentric retrospective study of low-dose rituximab in the treatment of 12 cases refractory or relapsed idiopathic autoimmune hemolytic anemia patients]. Zhonghua Xue Ye Xue Za Zhi 2017;38:1075-7. [PMID: 29365406 DOI: 10.3760/cma.j.issn.0253-2727.2017.12.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Richards AL, Kapp LM, Wang X, Howie HL, Hudson KE. Regulatory T Cells Are Dispensable for Tolerance to RBC Antigens. Front Immunol 2016;7:348. [PMID: 27698653 DOI: 10.3389/fimmu.2016.00348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gutiérrez Jomarrón I, López Rubio M, Morado Arias M, Arrizabalaga B, de la Iglesia S, Beneitez D, Sáez MI, Cervera A, Recasens V, Herrera A, Villegas AM; Grupo Español de Eritropatología. Autoimmune haemolytic anaemias: A retrospective study of 93 patients. Med Clin (Barc) 2020;154:331-7. [PMID: 31488259 DOI: 10.1016/j.medcli.2019.06.024] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Hwang SR, O'Dowd T, Markovic SN, Wolanskyj-Spinner AP. Recurrent checkpoint inhibitor-induced warm agglutinin autoimmune hemolytic anemia in a patient with metastatic melanoma. Am J Hematol 2020;95:E169-71. [PMID: 32243616 DOI: 10.1002/ajh.25812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Lesch S, Gill S. The promise and perils of immunotherapy. Blood Adv 2021;5:3709-25. [PMID: 34581774 DOI: 10.1182/bloodadvances.2021004453C] [Reference Citation Analysis]
33 Leone G, Pizzigallo E. Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases. Mediterr J Hematol Infect Dis 2015;7:e2015057. [PMID: 26543526 DOI: 10.4084/MJHID.2015.057] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
34 Sys J, Provan D, Schauwvlieghe A, Vanderschueren S, Dierickx D. The role of splenectomy in autoimmune hematological disorders: Outdated or still worth considering? Blood Reviews 2017;31:159-72. [DOI: 10.1016/j.blre.2017.01.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
35 Lauda-maillen M, Catroux M, Roy-peaud F, Souchaud-debouverie O, El Masmouhi B, Roblot P. Diagnostic et prise en charge de l’anémie hémolytique auto-immune à l’exclusion des formes secondaires à une cause néoplasique. Adéquation de la prise en charge au PNDS octobre 2009. La Revue de Médecine Interne 2017;38:648-55. [DOI: 10.1016/j.revmed.2017.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]